96 related articles for article (PubMed ID: 12661898)
1. Diagnostic value of urine deoxypyridinoline for detecting bone metastases in breast cancer patients.
Hou MF; Lin SB; Yuan SS; Tsai LY; Tsai SM; Hsieh JS; Huang TJ
Ann Clin Lab Sci; 2003; 33(1):55-61. PubMed ID: 12661898
[TBL] [Abstract][Full Text] [Related]
2. The course of the urinary DPD-crosslink secretion in metastatic breast cancer--a possibility for response assessment.
Lüftner D; Günther S; Flath B; Müller C; Echteroff K; Mergenthaler HG; Wernecke KD; Possinger K
Anticancer Res; 1999; 19(4A):2537-44. PubMed ID: 10470191
[TBL] [Abstract][Full Text] [Related]
3. Biochemical markers for assessment of bone metastases in patients with breast cancer.
Hou MF; Tsai LY; Tsai SM; Huang CJ; Huang YS; Hsieh JS; Chan HM; Wang JY; Chuang CH; Chen FM; Huang TJ
Kaohsiung J Med Sci; 1999 Aug; 15(8):452-60. PubMed ID: 10518361
[TBL] [Abstract][Full Text] [Related]
4. Urine calcium and deoxypyridinoline in assessment of response to local radiation therapy for metastatic bone disease.
Topkan E; Karaoglu A
J Exp Clin Cancer Res; 2007 Dec; 26(4):553-9. PubMed ID: 18365552
[TBL] [Abstract][Full Text] [Related]
5. Urinary excretion of deoxypyridinoline in patients with breast cancer.
Nguyen-Pamart M; Bonneterre J; Hecquet B
Anticancer Res; 1995; 15(4):1601-3. PubMed ID: 7654055
[TBL] [Abstract][Full Text] [Related]
6. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
7. [The clinical usefulness of urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer].
Takeuchi S; Saitoh H
Nihon Rinsho; 1998 Aug; 56(8):2077-81. PubMed ID: 9750511
[TBL] [Abstract][Full Text] [Related]
8. [Relationship of osteolytic biochemical indicators of bone metabolism with the therapeutic effect in breast cancer patients with bone metastases].
Li SF; Wang XR; Wang C; Chen Y; Ren L; Cui L; Tong ZS
Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):911-5. PubMed ID: 20193330
[TBL] [Abstract][Full Text] [Related]
9. Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases.
Walls J; Assiri A; Howell A; Rogers E; Ratcliffe WA; Eastell R; Bundred NJ
Br J Cancer; 1999 Jun; 80(8):1265-70. PubMed ID: 10376982
[TBL] [Abstract][Full Text] [Related]
10. Markers of bone resorption--measurement in serum, plasma or urine?
Huber F; Traber L; Roth HJ; Heckel V; Schmidt-Gayk H
Clin Lab; 2003; 49(5-6):203-7. PubMed ID: 15285175
[TBL] [Abstract][Full Text] [Related]
11. A comparison of bone-related biomarkers and CA27.29 to assess response to treatment of osseous metastatic breast cancer.
Lüfter D; Richter A; Günther S; Flath B; Akrivakis C; Geppert R; Wernecke KD; Possinger K
Anticancer Res; 2000; 20(6D):5099-105. PubMed ID: 11326676
[TBL] [Abstract][Full Text] [Related]
12. A comparison of methods for measuring serum and urinary markers of bone metabolism in cats.
DeLaurier A; Jackson B; Pfeiffer D; Ingham K; Horton MA; Price JS
Res Vet Sci; 2004 Aug; 77(1):29-39. PubMed ID: 15120950
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
[TBL] [Abstract][Full Text] [Related]
14. [The biochemical markers of bone remodeling in cancer patients with skeletal involvement].
Liubimova NV; Bronnikov IIu; Robins SP; Trapeznikova MF; Kushlinskiĭ NE
Vopr Onkol; 2000; 46(3):290-7. PubMed ID: 10976274
[TBL] [Abstract][Full Text] [Related]
15. Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy.
Kitatani K; Nakatsuka K; Naka H; Miki T; Morii H; Nishizawa Y
J Bone Miner Metab; 2003; 21(4):217-24. PubMed ID: 12811626
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of pyridinium crosslinks and CA 15-3 as markers in metastatic bone breast carcinoma.
Massidda B; Ionta MT; Foddi MR; Mascia L; Bruder F; Aloi MB; Meleddu C; Giannoni MN
Anticancer Res; 1996; 16(4B):2221-3. PubMed ID: 8694547
[TBL] [Abstract][Full Text] [Related]
18. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
19. [Role of biochemical indices as metastatic markers in patients with prostatic cancer invading skeleton].
Liubimova NV; Trapeznikova MF; Robins SP; Ognerubov SA; Kushlinskiĭ NE
Urologiia; 2000; (4):15-9. PubMed ID: 11186686
[TBL] [Abstract][Full Text] [Related]
20. Reference value for urinary deoxypyridinoline as a specific marker for measuring bone resorption in Thais.
Pidetcha P; Intramanee S; Patrakarn K; Leelahakul P; Fongsupa S
J Med Assoc Thai; 1999 Nov; 82(11):1136-41. PubMed ID: 10659549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
